Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 20/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13248430 | 0.85 | MAPKAPK2 (0.79) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248493 | 0.85 | MAPKAPK2 (0.79) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL2993727 | 0.84 | MAPKAPK2 (0.76) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248492 | 0.83 | MAPKAPK2 (0.73) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248527 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248495 | 0.83 | MAPKAPK2 (0.75) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248504 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248537 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL13248502 | 0.83 | MAPKAPK2 (0.75) | MAPKAPK2MAPK1MAP2K1 | |
| SCHEMBL2990252 | 0.83 | MAPKAPK2 (1.00) | MAPKAPK2MAPK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPK1 33/4885MAP2K1 65/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPK1 33/4885MAP2K1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.